Ceftaroline fosamil - AbbVie/Sumitomo Pharma/Takeda
Alternative Names: Ceftaroline acetate; CX-0903; DSP-5990; PPI-0903; TAK-599; Teflaro; ZinforoLatest Information Update: 05 Nov 2023
At a glance
- Originator Takeda
- Developer AbbVie; Allergan; AstraZeneca; Cerexa; Forest Laboratories; Pfizer; Sumitomo Pharma; Wayne State University
- Class Antibacterials; Azabicyclo compounds; Cephalosporins; Pyridinium compounds; Small molecules; Thiadiazoles
- Mechanism of Action Cell wall inhibitors; Penicillin-binding protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Community-acquired pneumonia; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
- Registered Bacteraemia
- Phase II Sepsis
- No development reported Bacterial infections
- Discontinued Osteomyelitis